IP Library › Granted Patent US 12,686,680

Granted Patent B2

US 12,686,680 · App. 17/782,615 · Granted Jul 21, 2026

Substituted pyrazolo[1,5-α]pyrimidines as CRF receptor antagonists

Inventors: Neil J. Ashweek (San Diego, CA); John P. Williams (San Diego, CA); Lev Alexander Zegelman (San Diego, CA); Christina Marie Costa (San Diego, CA); Scott Stirn (San Diego, CA); Shawn Branum (San Diego, CA); Jackie Le (San Diego, CA); John Lloyd Tucker (San Diego, CA); Brian M. Cochran (San Diego, CA); David Kucera (San Diego, CA); Donald Hettinger (San Diego, CA); Max A. Mellmer (San Diego, CA)

Assignee: Neurocrine Biosciences, Inc.

C07D487/04 A61P5/00 C07D231/54 C07D233/20 G01N33/74

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,686,680
App. No.: 17/782,615
Filed: Jun 3, 2022
Granted: Jul 21, 2026
Kind: B2
Examiner: WILLIS, DOUGLAS M
Art Unit: 1624
USPC: 514/247

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Compounds are provided herein that antagonize corticotropin-releasing factor (CRF) receptors, in particular CRF receptor 1 (CRF 1 ), as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

Claims (96)

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

R 1 is H or C 1-6 alkyl;

R 2 is C 3-10 cycloalkyl, 4- to 14-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl;

wherein the C 3-10 cycloalkyl, 4- to 14-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-Cy, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(N e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , and Cy; and

wherein each C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 haloalkyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(R e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a ,

OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d ;

each Cy is independently C 3-10 cycloalkyl, 4- to 14-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl, wherein each C 3-10 cycloalkyl, 4- to 14-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e1 )NR c1 R d1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , NR c1 R d1 , NR c1 C(NR e1 )NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)NR c1 R d1 , NR c1 C(O)OR a1 , NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , SR a1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R d1 ;

each R a is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R b is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R c is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R d is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ; or

any R c and R d , taken together with the nitrogen atom to which they are attached, independently forms a 4- to 7-membered heterocycloalkyl, wherein each 4- to 7-membered heterocycloalkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R a1 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R b1 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R c1 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a 2, NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R d1 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-10 aryl, 4- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR e2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ; or

any R c1 and R d1 , taken together with the nitrogen atom to which they are attached, independently forms a 4- to 7-membered heterocycloalkyl, wherein each 4- to 7-membered heterocycloalkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C(NR e2 )NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(NR c2 )NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , SR a2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R a2 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R b2 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R c2 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R d2 is independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, or 5- to 10-membered heteroaryl, wherein each C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-C 3-7 cycloalkyl, C 1-4 alkylene-4- to 10-membered heterocycloalkyl, C 1-4 alkylene-C 6-10 aryl, C 1-4 alkylene-5- to 10-membered heteroaryl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, 4- to 10-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R e is independently H, CN, or C 1-4 alkyl;

each R e1 is independently H, CN, or C 1-4 alkyl; and

each R e2 is independently H, CN, or C 1-4 alkyl;

with the provisos that:

(1) any ring-forming carbon atom or any ring-forming nitrogen atom of any aforementioned heterocycloalkyl is optionally and independently substituted with one ═O substituent; and

(2) any ring-forming sulfur atom of any aforementioned heterocycloalkyl is optionally and independently substituted with one or two ═O substituents.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is C 1-6 alkyl.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is CH 2 CH 2 CH 3 .

4 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is C 6-10 aryl or 5- to 10-membered heteroaryl;

wherein the C 6-10 aryl or 5- to 10-membered heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-Cy, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(NR e )NR c R d , C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , and Cy; and

wherein each C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 haloalkyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(NR e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d .

5 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is phenyl or 5- or 6-membered heteroaryl;

wherein the phenyl or 5- or 6-membered heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-Cy, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(NR e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , and Cy; and

wherein each C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 haloalkyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(R e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d .

6 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is phenyl, pyrazolyl, isoxazolyl, thiazolyl, triazolyl, thiadiazolyl, pyridinyl, or pyrimidinyl;

wherein the phenyl, pyrazolyl, isoxazolyl, thiazolyl, triazolyl, thiadiazolyl, pyridinyl, or pyrimidinyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-4 alkylene-Cy, C 2-6 alkenyl, C 2-6 alkynyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , R c C(NR e )NR c R d , NR c C(O)R b , NR c C(O)NR d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , and Cy; and

wherein each C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl substituent is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 haloalkyl, C(NR e )NR c R d , C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(NR e )NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O)R b , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , OC(O)NR c R d , SR a , S(O)R b , S(O)NR c R d , S(O) 2 R b , and S(O) 2 NR c R d .

7 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is phenyl, pyrazol-1-yl, isoxazol-4-yl, 2-(dimethylamino)thiazol-4-yl, 1,2,4-triazol-1-yl, 1,2,3-thiadiazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, or pyrimidin-5-yl.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

R 1 is C 1-6 alkyl;

R 2 is C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 6-10 aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C(O)R b , C(O)NR c R d , C(O)OR a , NR c R d , NR c C(O)R b , NR c C(O)NR c R d , NR c C(O)OR a , NR c S(O) 2 R b , NR c S(O) 2 NR c R d , OR a , OC(O)R b , S(O) 2 R b , and S(O) 2 NR c R d ;

each R a is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1 or 2 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , SR a2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R b is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1 or 2 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , SR a2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R c is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1 or 2 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , SR a2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R d is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1 or 2 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , SR a2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ; or

any R c and R d , taken together with the nitrogen atom to which they are attached, independently forms a 4- to 7-membered heterocycloalkyl, wherein each 4- to 7-membered heterocycloalkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-4 alkyl, C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , OR a2 , OC(O)R b2 , SR a2 , S(O) 2 R b2 , and S(O) 2 NR c2 R d2 ;

each R a2 is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R b2 is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl;

each R c2 is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl; and

each R d2 is independently H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein each C 1-6 alkyl is optionally and independently substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, NH 2 , OH, OC 1-6 alkyl, and OC 1-6 haloalkyl.

9 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

10 . A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

11 . A method for reducing the level of at least one biomarker in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof;

wherein reducing the level of at least one biomarker in the subject is effective to reduce the level of the at least one biomarker in the subject compared to the level of the at least one biomarker in the subject prior to administration of the therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof; and

wherein the at least one biomarker in the subject is selected from the group consisting of (a) androstenedione, (b) 17-hydroxyprogesterone (17-OHP), and (c) testosterone.

12 . A method for reducing the severity of at least one symptom of congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof;

wherein the at least one symptom of congenital adrenal hyperplasia (CAH) in the subject is selected from the group consisting of acne, a fertility problem, growth impairment, hirsutism, and precocious puberty.

13 . A method for reducing the dosage of corticosteroid needed by a subject to treat congenital adrenal hyperplasia (CAH) in the subject, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

14 . A method for reducing the severity of at least one side effect of glucocorticoid treatment in a subject having congenital adrenal hyperplasia (CAH), wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof;

wherein the at least one side effect of glucocorticoid treatment in the subject is selected from the group consisting of acne, adrenal suppression, akathisia, anxiety, avascular necrosis of the bone, cataract, central serous chorioretinopathy, cognitive impairment, coronary heart disease, a Cushingoid feature, Cushing's syndrome, delayed wound healing, delirium, dementia, depression, dermatoprosis, diabetes mellitus, dyslipidemia, easy bruising, ecchymosis, an erosion, euphoria, gastritis, gastrointestinal bleeding, glaucoma, growth suppression, hair loss, heart failure, hepatic steatosis, hirsutism, hyperglycemia, hypertension, irritability, ischemic heart disease, a mood change, mood lability, mydriasis, myopathy, an opportunistic ocular infection, osteoporosis, pancreatitis, peptic ulcer, a predisposition to an infection, ptosis, purpura, psychosis, a reactivation of a latent infection, skin atrophy, striae, suppression of cell-mediated immunity, visceral perforation, and weight gain.

15 . A method for treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

16 . The method of claim 15 , wherein the congenital adrenal hyperplasia (CAH) is classic congenital adrenal hyperplasia.

17 . The method of claim 16 , wherein the classic congenital adrenal hyperplasia is due to 21-hydroxylase deficiency.

18 . The method of claim 16 , wherein the subject has a mutation in the CYP21A2 gene located on chromosome 6p21.

19 . The method of claim 16 , wherein the subject does not have a mutation of the 11β-hydroxylase gene CYP11B1 (11β-OH CAH).

20 . The method of claim 16 , wherein the method further comprises administering to the subject a therapeutically effective amount of a glucocorticoid.

21 . The method of claim 20 , wherein the glucocorticoid is selected from the group consisting of dexamethasone, hydrocortisone, prednisolone, and prednisone.

22 . A method for treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises:

(i) measuring the level of at least one biomarker in a biological sample obtained from the subject, wherein the at least one biomarker obtained from the subject is selected from the group consisting of (a) androstenedione, (b) 17-hydroxyprogesterone (17-OHP), and (c) testosterone;

(ii) analyzing the level of the at least one biomarker in the biological sample obtained from the subject to determine if the level of the at least one biomarker in the biological sample obtained from the subject is elevated compared to a healthy subject not having congenital adrenal hyperplasia (CAH); and

(iii) administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, if the subject is determined to have an elevated level of at least one biomarker selected from the group consisting of (a) androstenedione, (b) 17-hydroxyprogesterone (17-OHP), and (c) testosterone.

23 . A compound having the structure:

24 . A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and the compound of claim 23 .

25 . A method for reducing the level of at least one biomarker in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 23 ;

wherein the at least one biomarker in the subject is selected from the group consisting of (a) androstenedione, (b) 17-hydroxyprogesterone (17-OHP), and (c) testosterone.

26 . A method for reducing the severity of at least one symptom of congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 23 ;

27 . A method for reducing the dosage of corticosteroid needed by a subject to treat congenital adrenal hyperplasia (CAH) in the subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 23 .

28 . A method for reducing the severity of at least one side effect of glucocorticoid treatment in a subject having congenital adrenal hyperplasia (CAH), wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 23 ;

29 . A method for treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 23 .

30 . The method of claim 29 , wherein the congenital adrenal hyperplasia (CAH) is classic congenital adrenal hyperplasia.

31 . The method of claim 30 , wherein the classic congenital adrenal hyperplasia is due to 21-hydroxylase deficiency.

32 . The method of claim 30 , wherein the subject has a mutation in the CYP21A2 gene located on chromosome 6p21.

33 . The method of claim 30 , wherein the subject does not have a mutation of the 11b-hydroxylase gene CYP11B1 (11b-OH CAH).

34 . The method of claim 30 , wherein the method further comprises administering to the subject a therapeutically effective amount of a glucocorticoid.

35 . The method of claim 34 , wherein the glucocorticoid is selected from the group consisting of dexamethasone, hydrocortisone, prednisolone, and prednisone.

36 . A method for treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, wherein the method comprises:

(iii) administering to the subject a therapeutically effective amount of the compound of claim 23 , if the subject is determined to have an elevated level of at least one biomarker selected from the group consisting of (a) androstenedione, (b) 17-hydroxyprogesterone (17-OHP), and (c) testosterone.

Assignments (2)

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2026

From: NEUROCRINE BIOSCIENCES, INC.

To: JPMORGAN CHASE BANK, N.A.

Reel/Frame 075670/0001 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022

From: ASHWEEK, NEIL J.; WILLIAMS, JOHN P.; ZEGELMAN, LEV ALEXANDER; COSTA, CHRISTINA MARIE; STIRN, SCOTT; BRANUM, SHAWN; LE, JACKIE; TUCKER, JOHN LLOYD; COCHRAN, BRIAN M.; KUCERA, DAVID; HETTINGER, DONALD; MELLMER, MAX A.

To: NEUROCRINE BIOSCIENCES, INC.

Reel/Frame 060911/0053 →

Continuity (2)

Provisional Application 62943517 · Dec 4, 2019

Related Publication 20230065034A1 · Mar 2, 2023

References Cited (400)

US 5464847A · Courtemanche et al. · 1995 [cited by applicant]

US 6344470B1 · Fontaine et al. · 2002 [cited by applicant]

US 6365180B1 · Meyer et al. · 2002 [cited by applicant]

US 6531475B1 · Haddach et al. · 2003 [cited by applicant]

US 6586456B1 · Fontaine et al. · 2003 [cited by applicant]

US 6610678B2 · Huang et al. · 2003 [cited by applicant]

US 6664261B2 · Chen et al. · 2003 [cited by applicant]

US 6806282B2 · Geslin et al. · 2004 [cited by applicant]

US 7276526B2 · Termin et al. · 2007 [cited by applicant]

US 7297708B2 · Termin et al. · 2007 [cited by applicant]

US 7951803B2 · Cole et al. · 2011 [cited by applicant]

US 8030304B2 · Chen et al. · 2011 [cited by applicant]

US 8153127B2 · Paez-Pereda et al. · 2012 [cited by applicant]

US 8314249B2 · Fazekas et al. · 2012 [cited by applicant]

US 8420679B2 · Fontaine et al. · 2013 [cited by applicant]

US 9351517B2 · Bromley · 2016 [cited by applicant]

US 10758490B2 · Viladot Petit et al. · 2020 [cited by applicant]

US 10849908B2 · Howerton et al. · 2020 [cited by applicant]

US 10898477B2 · Madhavi et al. · 2021 [cited by applicant]

US 10905690B2 · Grigoriadis · 2021 [cited by applicant]

US 11007201B2 · Howerton et al. · 2021 [cited by applicant]

US 11304950B2 · Howerton et al. · 2022 [cited by applicant]

US 11311544B2 · Grigoriadis · 2022 [cited by applicant]

US 11583502B2 · Wu et al. · 2023 [cited by applicant]

US 11730739B2 · Grigoriadis · 2023 [cited by applicant]

US 11858932B2 · Barnes et al. · 2024 [cited by applicant]

US 12128033B2 · Becker et al. · 2024 [cited by applicant]

US 12214084B2 · Osaki et al. · 2025 [cited by applicant]

US 12383536B2 · Smith et al. · 2025 [cited by applicant]

US 12582634B2 · Becker et al. · 2026 [cited by applicant]

US 20050209250A1 · Romano · 2005 [cited by applicant]

US 20060078623A1 · Dhoot et al. · 2006 [cited by applicant]

US 20070281919A1 · Fontaine et al. · 2007 [cited by applicant]

US 20090203755A1 · Richard · 2009 [cited by applicant]

US 20100216751A1 · Jacob et al. · 2010 [cited by applicant]

US 20100222339A1 · Chen et al. · 2010 [cited by applicant]

US 20130183383A1 · Phang et al. · 2013 [cited by applicant]

US 20150094310A1 · Holsboer · 2015 [cited by applicant]

US 20150284362A1 · Bersot et al. · 2015 [cited by applicant]

US 20170020877A1 · Grigoriadis · 2017 [cited by applicant]

US 20190231781A1 · Grigoriadis · 2019 [cited by applicant]

US 20200255436A1 · Howerton et al. · 2020 [cited by applicant]

US 20210137926A1 · Grigoriadis · 2021 [cited by applicant]

US 20210361659A1 · Grigoriadis · 2021 [cited by applicant]

US 20220023266A1 · Farber et al. · 2022 [cited by applicant]

US 20220133742A1 · Ghosh et al. · 2022 [cited by applicant]

US 20220211711A1 · Howerton et al. · 2022 [cited by applicant]

US 20220409592A1 · Smith et al. · 2022 [cited by applicant]

US 20230233534A1 · Palmer et al. · 2023 [cited by applicant]

US 20230255942A1 · Farber et al. · 2023 [cited by applicant]

US 20230286932A1 · Palmer et al. · 2023 [cited by applicant]

US 20230295161A1 · Barnes et al. · 2023 [cited by applicant]

US 20240024330A1 · Loewen et al. · 2024 [cited by applicant]

US 20240058342A1 · Grigoriadis · 2024 [cited by applicant]

US 20240238257A1 · Becker et al. · 2024 [cited by applicant]

CN 1370154 · 2002 [cited by applicant]

CN 101381314A · 2009 [cited by applicant]

CN 102414185 · 2012 [cited by applicant]

CN 106102740 · 2016 [cited by applicant]

CN 107438606 · 2017 [cited by applicant]

EP 3784233B1 · 2024 [cited by applicant]

JP 2002030048A · 2002 [cited by applicant]

JP 4949582 · 2012 [cited by applicant]

JP 2012525368A · 2012 [cited by applicant]

JP 2013231063 · 2013 [cited by applicant]

JP 2015516979A · 2015 [cited by applicant]

JP 2018516231A · 2018 [cited by applicant]

RU 2523793C2 · 2014 [cited by applicant]

RU 2667977C2 · 2018 [cited by applicant]

WO WO1987005297 · 1987 [cited by applicant]

WO WO1998008846 · 1998 [cited by applicant]

WO WO1998011075 · 1998 [cited by applicant]

WO WO1999010350 · 1999 [cited by applicant]

WO WO2000059888 · 2000 [cited by applicant]

WO WO2001005776 · 2001 [cited by applicant]

WO WO2003006015 · 2003 [cited by applicant]

WO WO2003022820A1 · 2003 [cited by applicant]

WO WO2006044821 · 2006 [cited by applicant]

WO WO2006044958 · 2006 [cited by applicant]

WO WO2006102194 · 2006 [cited by applicant]

WO WO2006107784 · 2006 [cited by applicant]

WO WO2006116412 · 2006 [cited by applicant]

WO WO2006126718 · 2006 [cited by applicant]

WO WO2007069565 · 2007 [cited by applicant]

WO WO2007069671 · 2007 [cited by applicant]

WO WO2007090631 · 2007 [cited by applicant]

WO WO2007104053A2 · 2007 [cited by applicant]

WO WO2007105113 · 2007 [cited by applicant]

WO WO2007137227 · 2007 [cited by applicant]

WO WO2008036541 · 2008 [cited by applicant]

WO WO2008036579 · 2008 [cited by applicant]

WO WO2008051533 · 2008 [cited by applicant]

WO WO2008082003 · 2008 [cited by applicant]

WO WO2008083070 · 2008 [cited by applicant]

WO WO2008136377 · 2008 [cited by applicant]

WO WO2009008552 · 2009 [cited by applicant]

WO WO2009144632 · 2009 [cited by applicant]

WO WO2010014280 · 2010 [cited by applicant]

WO WO2010014687 · 2010 [cited by applicant]

WO WO2010015628 · 2010 [cited by applicant]

WO WO2010015655 · 2010 [cited by applicant]

WO WO2010062718 · 2010 [cited by applicant]

WO WO2010096426 · 2010 [cited by applicant]

WO WO2010125414 · 2010 [cited by applicant]

WO WO2011043381 · 2011 [cited by applicant]

WO WO2011043387 · 2011 [cited by applicant]

WO WO2011092290 · 2011 [cited by applicant]

WO WO2011092293 · 2011 [cited by applicant]

WO WO2011095450 · 2011 [cited by applicant]

WO WO2011128783A2 · 2011 [cited by applicant]

WO WO2013155464 · 2013 [cited by applicant]

WO WO2013160315 · 2013 [cited by applicant]

WO WO2013160317 · 2013 [cited by applicant]

WO WO2014151109A1 · 2014 [cited by applicant]

WO WO2015112642 · 2015 [cited by applicant]

WO WO2015155664A1 · 2015 [cited by applicant]

WO WO2015159170A2 · 2015 [cited by applicant]

WO WO2016065177 · 2016 [cited by applicant]

WO WO2016127133 · 2016 [cited by applicant]

WO WO2016156575A2 · 2016 [cited by applicant]

WO WO2016156576 · 2016 [cited by applicant]

WO WO2017031325A1 · 2017 [cited by applicant]

WO WO2017218379A1 · 2017 [cited by applicant]

WO WO2018102552 · 2018 [cited by applicant]

WO WO2018213634A1 · 2018 [cited by applicant]

WO WO2018219804 · 2018 [cited by applicant]

WO WO2019036472 · 2019 [cited by applicant]

WO WO2019036503 · 2019 [cited by applicant]

WO WO2019210266 · 2019 [cited by applicant]

WO WO2020115555 · 2020 [cited by applicant]

WO WO2021016208 · 2021 [cited by applicant]

WO WO2021062246 · 2021 [cited by applicant]

WO WO2021111179A1 · 2021 [cited by applicant]

WO WO2021113263 · 2021 [cited by applicant]

WO WO2021250468 · 2021 [cited by applicant]

WO WO2021252669 · 2021 [cited by applicant]

WO WO2022036123A1 · 2022 [cited by applicant]

WO WO2022046905 · 2022 [cited by applicant]

WO WO2022153062A1 · 2022 [cited by applicant]

WO WO2022184549A1 · 2022 [cited by applicant]

WO WO2024206769 · 2024 [cited by applicant]

[No Author Listed], “Assessing the Effects of Food on Drugs in INDs and NDAs—Clinical Pharmacology Considerations Guidance for Industry,” U.S. Department of Health and Human Services, Food and Drug Administration, Cente… [cited by applicant]

[No Author Listed], “Form 8-K: Current Report,” Securities and Exchange Commission, Washington, D.C., Apr. 5, 2000, 4 pages. [cited by applicant]

[No Author Listed], “IUPAC-IUB, Commission on Biochemical Nomenclature—Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)*—Revised Recommendations (1971),” Biochemistry, 1972, 11(5):942-944. [cited by applicant]

[No Author Listed], “Neurocrine announces top-line results of corticotropin releasing factor antagonist GSK561679 for treatment of major depressive disorder,” Neurocrine Biosciences, Inc., Sep. 14, 2010, 1 page. [cited by applicant]

[No Author Listed], “Sanofi-Aventis: strong performance of growth platforms in Q1 2011,” Sanofi Press Release, Apr. 28, 2011, 13 pages. [cited by applicant]

[No Author Listed], “Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020,” Neurocrine Biosciences Inc., Jun. 8, 2020, 3 pages. [cited by applicant]

[No Author Listed], “Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classical Congenital Adrenal Hyperplasia at ENDO 2021,” Neurocrine Biosciences Inc., Mar. 20, 2021, 5 pages. [cited by applicant]

[No Author Listed], “Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Meeting,” Spruce Biosciences, Mar. 17, 2021, 2 page… [cited by applicant]

Abdellatif, “Microparticles Formulation as a Targeting Drug Delivery System,” J Nanomed Res., 2017, 6(2):00151. [cited by applicant]

Alejandro et al., “Behavioral, Adrenal, and Sympathetic Responses to Long-Term Administration of an Oral Corticotropin-Releasing Hormone Receptor Antagonist in a Primate Stress Paradigm,” The Journal of Clinical Endocri… [cited by applicant]

Allen et al., “Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep),” Sleep Medicine, May 1, 2009;10(5):531-9. [cited by applicant]

Ambroziak et al., “Congenital adrenal hyperplasia due to 21-hydroxylase deficiency—management in adults,” Polish Journal of Endocrinology, 2010, 61:142-155. [cited by applicant]

Anthenelli et al., “Sex Differences in the ACTH and Cortisol Response to Pharmacological Probes are Stressor-Specific and Occur Regardless of Alcohol Dependence History,” Psychoneuroendocrinology, Aug. 2018, 94:72-82. [cited by applicant]

Arlt et al., “Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients,” J Clin Endocrinol Metab., Nov. 2010, 95(11):5110-21. [cited by applicant]

Arvanitis, AG., et al., “Non-Peptide Corticotropin-Releasing Hormone Antagonists: Syntheses and Structure-Activity Relationships of 2-Anilinopyrimidines and—triazines,” J. Med. Chem., 1999, 42(5): 805-818. [cited by applicant]

Auchus et al., “A pharmacokinetic and biomarker study of the corticotropin-releasing factor receptor antagonist NBI-77860 in adult females with classic, 21-hydroxylase deficiency, congenital adrenal hyperplasia (CAH),” … [cited by applicant]

Auchus et al., “Approach to the patient: the adult with congenital adrenal hyperplasia,” J Clin Endocrinol Metab., Jul. 2013, 98(7):2645-55. [cited by applicant]

Auchus et al., “Crinecerfont (NBI-74788), a novel CRFI receptor antagonist, reduces adrenal androgens and precursors in patients with classic congenital adrenal hyperplasia: Results from a phase 2, multiple-dose study,”… [cited by applicant]

Auchus et al., “Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia,” The Journal of Clinical Endocrinology & Metabolism, 2022, 107(3):801-812. [cited by applicant]

Auchus et al., “OR18-4 Crinecerfont (NBI-74788), a Novel CRFI Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia,” Journal of the Endocrine Society, 2… [cited by applicant]

Auchus et al., “Response to Crinecerfont Treatment in Adults with Classic Congenital Adrenal Hyperplasia Is Correlated with Elevated Baseline Hormone Levels But Not Glucocorticoid Dose,” Abstract submitted to ECE for co… [cited by applicant]

Auchus et al., “The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase … [cited by applicant]

Auchus et al., “The effects of crinecerfont (NBI-74788), a novel CRF1 receptor antagonist, on adrenal androgens and precursors in patients with classic congenital adrenal hyperplasia: Results from a multiple-dose phase … [cited by applicant]

Auchus RJ, et al., “Management of the adult with congenital adrenal hyperplasia,” Int J Ped Endocrinol., 2010, Article ID 614107: 1-9. [cited by applicant]

Bachelot A, et al., “Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency,” Int J Ped Endocrinol., 2010, Article ID 326275: 1-7. [cited by applicant]

Bakshi VP, et al., “Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala”, J. Neurosci., 2002, 22(7): 2926-2935. [cited by applicant]

Bale et al., “Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems,” Crit Rev Ther Drug Carrier Syst., 2016, 33(4):309-361. [cited by applicant]

Barreau F et al., “Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay,” Journal of Physiology-London, 20… [cited by applicant]

Behan DP et al., “Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders,” Molecular Psychiatry, 1996, 1(4):265-277. [cited by applicant]

Belza et al., “A systematic review of studies using the multidimensional assessment of fatigue scale,” Journal of Nursing Measurement, May 1, 2018;26(1):36-74. [cited by applicant]

Belza, “Comparison of self-reported fatigue in rheumatoid arthritis and controls,” J Rheumatol., Apr. 1995, 22(4):639-643. [cited by applicant]

Benedetti et al., “The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect,” J Neurosci., Nov. 15, 2006, 26(46):12014-12022. [cited by applicant]

Berge et al., “Pharmaceutical salts,” Journal of Pharmaceutical Sciences, 1977, 66(1):1-9. [cited by applicant]

Bleicken B, et al., “Improvement of health-related quality of life in adult women with 21-hydroxylase deficiency over a seven-year period,” Endocr J., 2012, 59(10):931-939. [cited by applicant]

Blume et al., “Oral medicine acceptance in infants and toddlers: measurement properties of the caregiver-administered Children's acceptance tool (CareCAT),” BMC pediatrics, 2018, 18:117. [cited by applicant]

Bonfig et al., “Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty,” J Clin Endocrinol Metab., May 2007, 92(5):1635-1639. [cited by applicant]

Bonfig W et al., “Hydrocortisone Dosing During Puberty in Patients With Classical Congenital Adrenal Hyperplasia: An Evidence-Based Recommendation,” J Clin Endocrinol Metab., 2009, 94(10):3882-3888. [cited by applicant]

Bornstein et al., “Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation,” Endocrinology, 1998, 139(4): 1546-1555. [cited by applicant]

Brazier et al., “Validating the SF-36 health survey questionnaire: new outcome measure for primary care,” BMJ, Jul. 18, 1992, 305(6846):160-164. [cited by applicant]

Brunson KL, et al., “Corticotropin-Releasing Hormone (CRH) Downregulates the Function of Its Receptor (CRF1) and Induces CRF1 Expression in Hippocampal and Cortical Regions of the Immature Rat Brain,” Experimental Neuro… [cited by applicant]

Buxton et al., “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination,” Goodman & Gilman's The Pharmacological Basis of Therapeutics., Brunton L.L. ed., 12th ed. 2011, Chapter 2, 2… [cited by applicant]

Caira, “Crystalline polymorphism of organic compounds,” Design of Organic Solids, 1998, pp. 163-208. [cited by applicant]

Caresfoundation.org [Online], “Emergency Instructions - Treatment for Congenital Adrenal Hyperplasia in times of stress,” 2014, [retrieved on Mar. 6, 2023], retrieved from: URL<https://caresfoundation.org/wp-content/upl… [cited by applicant]

CAS Registry No., 321839-75-2, Feb. 15, 2001, 1 page. [cited by applicant]

Chakhtoura Z. et al., “Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency,” Eur J Endocrinol., 2008, 158(6):879-887. [cited by applicant]

Charmandari et al., “Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” J Endocrinol, Apr. 2001, 169(1):65-70. [cited by applicant]

Chatzaki, E, et al., “CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon,” Journal of Neurochemistry, 2004, 90: 309-316. [cited by applicant]

Chen C, et al., “NBI 30775 (R121919), an Orally Active Antagonist of the Corticotropin-releasing Factor (CRF) Type-1 Receptor for the Treatment of Anxiety and Depression,” Drug Development Research, 2005, 65(4):216-226. [cited by applicant]

Chen C, et al., “1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-Acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-Releasing factor-1 (CRF1) receptor antagoni… [cited by applicant]

Chen C, et al., “Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists,” J. Med. Chem., 1996, 39(22): 4358-4360. [cited by applicant]

Chen C, et al., “Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility” Bioorganic & Medicinal Chemistry Letters, 2004… [cited by applicant]

Chen et al., “Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a] pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active cortico… [cited by applicant]

Chen Y, et al., “Cellular and molecular mechanisms of hippocampal activation by acute stress are age-dependent,” Molecular Psychiatry, 2006, 11: 992-1002. [cited by applicant]

Chen Y, et al., “Modulation of dendritic differentiation by corticotropin-releasing factor in the developing hippocampus,” Proceedings of the National Academy of Sciences, 2004, 101(44): 15782-15787. [cited by applicant]

Cheng and Speiser, “Treatment outcomes in congenital adrenal hyperplasia,” Adv Pediatr., 2012, 59(1):269-281. [cited by applicant]

Claahsen-van der Grinten et al., “Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21- hydroxylase deficiency,” Eur J Endocrinol., Sep. 2007, 157(3):339-344. [cited by applicant]

Claustre et al., “Effects of the Vasopressin (V [cited by applicant]

Clinicaltrials.gov [Online], “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia,” First Posted Aug. 5, 2019, [Retrieved on Nov. 30, 2022]… [cited by applicant]

Clinicaltrials.gov, “A study in patients with irritable bowel syndrome to measure hormone response after dosing with GW876008 and Gsk561679,” U.S. National Library of Medicine, Aug. 6, 2007, retrieved on Jun. 11, 2020, … [cited by applicant]

Clinicaltrials.gov, “A study of the effects of a new antidepressant treatment (GSK561679) in females with major depressive disorder,” U.S. National Library of Medicine, Aug. 13, 2008, retrieved on Jun. 11, 2020, retriev… [cited by applicant]

Clinicaltrials.gov, “A study to compare the putative anxiolytic effect of 2 new drugs in subjects with social anxiety disorder,” U.S. National Library of Medicine, Nov. 7, 2007, retrieved on Jun. 11, 2020, retrieved fro… [cited by applicant]

Clinicaltrials.gov, “CRF1 antagonist GSK561679 in alcoholism,” U.S. National Library of Medicine, Aug. 24, 2010, retrieved on Sep. 25, 2020, retrieved from URL: https://clinicaltrials.gov/ct2/show/NCT01187511?term=NCT01… [cited by applicant]

Clinicaltrials.gov, “Evaluation of GSK561679 in women with post-traumatic stress disorder,” U.S. National Library of Medicine, Nov. 25, 2009, retrieved on Jun. 11, 2020, retrieved from URL: https://clinicaltrials.gov/ct… [cited by applicant]

Collier et al., “Radiosynthesis and In-Vivo Evaluation of the Pseudopeptide δ-Opioid Antagonist [ [cited by applicant]

Cottone P, et al., “CRF system recruitment mediates dark side of compulsive eating,” Proceedings of the National Academy of Sciences, 2009, 106(47): 20016-20020. [cited by applicant]

Cui et al., “Modification of sample size in group sequential clinical trials,” Biometrics, 1999, 55(3):853-857. [cited by applicant]

Curtis AL, et al., “Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies,” Journal of Pharmacology and Experimental Therapeutics, 1994, 268(1): 359-365. [cited by applicant]

Dai et al., “A Generic Headspace GC Method for Residual Solvents in Pharmaceuticals: Benefits, Rationale, and Adaptations for New Chemical Entities,” LCGC North America, 2010, 28(1):54-66. [cited by applicant]

Dauber et al., “Nocturnal dexamethasone versus Hydrocortisone for the treatment of children with congenital adrenal hyperplasia,” Int. J. of Pediatric Endocrinology, 2010, 2010(1):347636. [cited by applicant]

de Vries et al., “Mental health of a large group of adults with disorders of sex development in six European countries,” Psychosomatic Medicine, 2019, 81(7):629-640. [cited by applicant]

Deak et al., “The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress,” Endocrinology, 1999, 140(1):79-86. [cited by applicant]

Derendorf et al., “Pharmacokinetics and oral bioavailability of hydrocortisone,” J Clin Pharmacol. May 1991, 31(5):473-476. [cited by applicant]

Douma et al., “CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents,” Psychopharmacology, 2014, 231:1289-1303. [cited by applicant]

Dournes et al., “Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF [cited by applicant]

Doyon et al., “Effects of the CRF [cited by applicant]

Dudzinska B, et al., “Sexual Well-Being in Adult Male Patients with Congenital Adrenal Hyperplasia,” Int J Endocrinol., 2014, ID 469289: 1-9. [cited by applicant]

Dunn et al., “Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?” Brain Res Brain Res Rev., May 1990-Aug. 15(2):71-100. [cited by applicant]

Dyck B, et al., “Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core,” J. Med. Chem., 2005, 48(12): 4100-4110. [cited by applicant]

Elder et al., “The utility of sulfonate salts in drug development,” Journal of Pharmaceutical Sciences, Jan. 1, 2010, 99(7):2948-2961. [cited by applicant]

El-Maouche et al., “Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia,” Clinical Endocrinology, 2019, 91(2):247-255. [cited by applicant]

El-Maouche et al., “Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia,” The Journal of Clinical Endocrinology & Metabolism, 2018, 103(6):2336-2345. [cited by applicant]

El-Maouche et al., “Congenital Adrenal Hyperplasia,” Lancet., Nov. 11, 2017, 390:2194-2210. [cited by applicant]

Elnecave et al., “Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency,” J Pediatr Endocrinol Metab., Dec. 2008, 21(12):1155-62. [cited by applicant]

Esteban et al., “Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry,” J Clin Endocrinol Metab., Jan. 1991, 72(1):39-45. [cited by applicant]

EU Clinical Trials Register, “Abbreviated Style Clinical Study Report,” Sanofi- Aventis Group, Sep. 5, 2011, 4 pages. [cited by applicant]

Fahmy et al., “Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use,” Curr Mol Pharmacol., 2017, 10(4):270-281. [cited by applicant]

Falhammar et al., “Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia,” Eur J Endocrinol., Mar. 2012, 166(3):441-449. [cited by applicant]

Falhammar et al., “Fractures and bone mineral density in adult women with 21-hydroxylase deficiency,” J Clin Endocrinol Metab. Dec. 2007; 92(12):4643-4649. [cited by applicant]

Falhammar et al., “Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” J Clin Endocrinol Metab., Dec. 2014, 99(12):E2715-21. [cited by applicant]

Falhammar et al., “Quality of life, social situation, and sexual satisfaction, in adult males with congenital adrenal hyperplasia,” Endocrine, 2014, 47:299-307. [cited by applicant]

Finkielstain et al., “Clinical Characteristics of a Cohort of 244 Patients with Congenital Adrenal Hyperplasia,” J Clin Endocrinol Metab, 2012, 97(12):4429-4438. [cited by applicant]

Fleck et al., “Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor,” The Journal of Pharmacology and Experimental Therapeutics, 2012, 341(2):518-531. [cited by applicant]

Forest, “Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” Human Reproduction Update, 2004, 10(6): 469-485. [cited by applicant]

Frederic et al., “Radiosynthesis of [C-11]SSR126374, a new selective CRF1 antagonist,” Journal of Labelled Compounds & Radiopharmaceuticals, 2011, 54(1):273. [cited by applicant]

Fuqua et al., “Duration of suppression of adrenal steroids after glucocorticoid administration,” International Journal of Pediatric Endocrinology, 2010, 2010:1-8. [cited by applicant]

Gilban D, et al., “Health related quality of life of children and adolescents with congenital hyperplasia in Brazil,” Health Qual Life Outcomes, 2014, 12:107 (9 pages). [cited by applicant]

Gilligan et al., “Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases,” Curr. Opin. In Drug Discov. & Develop., 2004, 7(4)487-497. [cited by applicant]

Grammatopoulos et al., Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists, TRENDS in Endocrinology & Metabolism, 2002, 13(10):436-444. [cited by applicant]

Griebel et al., “4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin… [cited by applicant]

Grigoriadis DE, “Corticotropin-Releasing Factor Receptor Antagonists: Potential Novel Therapies for Human Disease,” Celltransmissions, 2003, 19(4): 3-10. [cited by applicant]

Grigoriadis DE, “The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders,” Expert Opin. Ther. Targets, 2005, 9(4): 651-684. [cited by applicant]

Grigoriadis DE, et al., “ [cited by applicant]

Grigoriadis DE, et al., “Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels,” Neuropsychopharmacology, 2009, 3… [cited by applicant]

Grigoriadis, DE, et al., “The CRF Receptor Structure, Function and Potential for Therapeutic Intervention,” Current Medicinal Chemistry—Central Nervous System Agents, 2001, 1(1): 63-97. [cited by applicant]

Gross RS, et al., “Design and Synthesis of Tricyclic Corticotropin-Releasing Factor-1 Antagonists,” J. Med. Chem., 2005, 48(18): 5780-5793. [cited by applicant]

Grossi et al., “Development and validation of the short version of the Psychological General Well-Being Index (PGWB-S),” Health and Quality of Life Outcomes, 2006, 4(1):1-8. [cited by applicant]

Gully et al., “4-(2-Chloro-4-methoxy-5-methylphenyl)- [cited by applicant]

Guo Z, et al., “Design and Synthesis of Tricyclic Imidazo[4,5-b]pyridin-2-ones as Corticotropin-Releasing Factor-1 Antagonists,” J. Med. Chem., 2005 , 48(16): 5104-5107. [cited by applicant]

Habib et al., “Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates,” Proceedings of the Nationa… [cited by applicant]

Halper et al., “Health-related quality of life in children with congenital adrenal hyperplasia,” Health Qual. Life Outcomes, 2017, 15(1):194. [cited by applicant]

Hamilton, “Needle Phobia: A Neglected Diagnosis,” J Fam Pract., Aug. 1995, 41(2):169-175. [cited by applicant]

Han et al., “Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHA… [cited by applicant]

Han TS, et al., “Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia,” Clin Endocrinol, 2013, 8:197-203. [cited by applicant]

Han TS, et al., “Relationship Between Final Height and Health Outcomes in Adults with Congenital Adrenal Hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE),” J Clin Endocrinol Meta… [cited by applicant]

Han TS, et al., “Treatment and health outcomes in adults with congenital adrenal hyperplasia,” Nat Rev Endocrinol., 2014, 10:115-124. [cited by applicant]

Hannah-Shmouni et al., “Genetics of Congenital Adrenal Hyperplasia,” Best Pract Res Clin Endocrinol Metab., Apr. 2009, 23(2):181-192. [cited by applicant]

Hauger RL, et al., “International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands,” Pharmacological Reviews, 2003, 55(1): 21-26. [cited by applicant]

He et al., “Changes in adrenal and gonadal androgens after 14-day treatment with a CRF1 receptor antagonist, crinecerfont (NBI-74788), in men with classic 21-hydroxylase deficiency,” Journal of the Endocrine Society, 20… [cited by applicant]

Heike et al., “Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects”, J Psych Res., Nov. 1, 2003, 37(8):525-533. [cited by applicant]

Heinrichs SC, et al., “Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective Antagonist,” Neuropsychopharmacology, 2002, 27:194… [cited by applicant]

Herdman et al., “Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L),” Qual Life Res., Dec. 2011, 20(10):1727-1736. [cited by applicant]

Hertzberg et al., “Birth prevalence rates of newborn screening disorders in relation to screening practices in the United States,” J Pediatr., Oct. 2011, 159(4):555-560. [cited by applicant]

Hines et al., “Spatial abilities following prenatal androgen abnormality: targeting and mental rotations performance in individuals with congenital adrenal hyperplasia,” Psychoneuroendocrinology, Nov. 2003, 28(8):1010-1… [cited by applicant]

Hoare et al., “Mechanism of Corticotropin-Releasing Factor Type I Receptor Regulation by Nonpeptide Antagonists,” Molecular Pharmacology, 2003, 63(3):751-756. [cited by applicant]

Hoare SRJ, et al., “Allosteric Ligands for the Corticotropin Releasing Factor Type 1 Receptor Modulate Conformational States Involved in Receptor Activation,” Molecular Pharmacology, 2008, 73(5): 1371-1380. [cited by applicant]

Hoare SRJ, et al., “Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands,” Peptides, 2003, 24(12): 1881-1897. [cited by applicant]

Hoare SRJ, et al., “Ligand Affinity for Amino-Terminal and Juxtamembrane Domains of the Corticotropin Releasing Factor Type I Receptor: Regulation by G-Protein and Nonpeptide Antagonists,” Biochemistry, 2004, 43(13): 39… [cited by applicant]

Hoare SRJ, et al., “Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor,” Biochemical Pharmacology, 2006, 72(2): 244-255. [cited by applicant]

Holm, “A simple sequentially rejective multiple test procedure,” Scandinavian Journal of Statistics, 1979, 65-70. [cited by applicant]

Huang CQ, et al., “Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, 2004, 14(15): 3943-3947. [cited by applicant]

Huang CQ, et al., “Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor1 (CRF1) receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, 2004, 14(… [cited by applicant]

Huang CQ, et al., “Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, 2003, 13(19): 3375-3379. [cited by applicant]

Huang CQ, et al., “Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists,” Bi… [cited by applicant]

Iranmanesh et al., “Glucose Ingestion Selectively Amplifies ACTH and Cortisol Secretory-Burst Mass and Enhances Their Joint Synchrony in Healthy Men,” J Endocrinol and Metab., Sep. 2011, 96(9):2882-2888. [cited by applicant]

Ising M, et al., “High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response,” Neuropsychopharmacology, 2007, 32:1941-1949. [cited by applicant]

Ivy AS, et al., “Hippocampal Dysfunction and Cognitive Impairments Provoked by Chronic Early-Life Stress Involve Excessive Activation of CRH Receptors,” J. Neurosci., 2010, 30(39):13005-13015. [cited by applicant]

Jain et al., “Spray Drying in Pharmaceutical Industry: A review,” Research Journal of Pharmaceutical Dosage Forms and Technology, Apr. 10, 2012, 4(2):74-79. [cited by applicant]

Jenkins-Jones et al., “Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia,” European Journal of Endocrinology, 2018, 178(4):309-320. [cited by applicant]

Jha et al., “SUN-371 Successful Induction of Fertility with Low-Dose Dexamethasone in a Patient with Congenital Adrenal Hyperplasia and Testicular Adrenal Rest Tumor,” Journal of the Endocrine Society, 2019, 3(Supplemen… [cited by applicant]

Johannsen et al., “Impaired cognitive function in women with congenital adrenal hyperplasia,” J Clin Endocrinol Metab., Apr. 2006, 91(4):1376-1381. [cited by applicant]

Katkade et al., “Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making,” J Multidiscip Healthc., 2018, 11:295-304. [cited by applicant]

Kehne et al., “Therapeutic Utility of Non-Peptidic CRF [cited by applicant]

Kiddoo DA, et al., “Impact of state of arousal and stress neuropeptides on urodynamic function in freely moving rats,” Am J Physiol Regul Integr Comp Physiol, 2006, 290:R1697-R1706. [cited by applicant]

Kim et al., “Cardiovascular Disease Risk in Adult Women with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency,” Semin Reprod Med, 2009, 27(4):316-321. [cited by applicant]

King et al., “Long-Term Corticosteroid Replacement and Bone Mineral Density in Adult Women with Classical Congenital Adrenal Hyperplasia,” The Journal of Clinical Endocrinology & Metabolism, 2006, 91(3):865-869. [cited by applicant]

Kitagawa et al., “Basic Pharmaceutical Science Textbook Series 20,” Pharmaceutical Science, 2nd print, Kagaku-Dojin Publishing Co., Inc., 2012, p. 16-19. [cited by applicant]

Koelsch et al., “The Impact of Acute Stress on Hormones and Cytokines, and How Their Recovery is Affected by Music-Evoked Positive Mood,” Sci Reps., Mar. 2016, 6:1-11. [cited by applicant]

Koob et al., “Update on Corticotropin-Releasing Factor Pharmacotherapy for Psychiatric Disorders: A Revisionist View,” Neuropsychopharmacology Reviews, 2012, 37:308-309. [cited by applicant]

Kosoyan HP, et al., “The CRF [cited by applicant]

Kulshreshtha B, et al., “Pubertal development among girls with classical congenital adrenal hyperplasia initiated on treatment at different ages,” Indian J Endocrinol Metab., 2012, 16(4):599-603. [cited by applicant]

Le Bas et al., “Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NKI receptor by spect,” Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44(S1):S280-S282. [cited by applicant]

Lehmacher et al., “Adaptive sample size calculations in group sequential trials,” Biometrics, 1999, 55(4):1286-1290. [cited by applicant]

Lekarev et al., “Adrenal disease in pregnancy,” Best Practice & Research, Clinical Endocrinology & Metabolism, Dec. 2011, 25(6):959-973. [cited by applicant]

Li et al., “The pharmacology of DMP696 and DMP904, non-peptidergic CRF [cited by applicant]

Liapakis G, et al., “Members of CRF Family and their Receptors: From Past to Future,” Current Medicinal Chemistry, 2011, 18(17):2583-2600. [cited by applicant]

Linder et al., “Cortisol production rate in childhood and adolescence,” J Pediatr, Dec. 1990, 117(6):892-896. [cited by applicant]

Liu J, et al., “Corticotropin-Releasing Factor and Urocortin I Modulate Excitatory Glutamatergic Synaptic Transmission,” Journal of Neuroscience, 2004, 24(16): 4020-4029. [cited by applicant]

Loechner et al., “Alternative Strategies for the Treatment of Classical Congenital Adrenal Hyperplasia: Pitfalls and Promises,” International Journal of Pediatric Endocrinology, vol. 2010, No. 1, Jun. 8, 2010, Article I… [cited by applicant]

Logachev et al., “Congenital Adrenal Hyperplasia: Modern Problems of Terminology and Treatment,” Pediatrics, Apr. 19, 2012, 91(3):130-135 pages (with English Translation). [cited by applicant]

Louis et al., “Antidepressant-like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 S Schedule in the Rat,” Neuropsychoph… [cited by applicant]

Lovenberg TW, et al., “Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain,” Proceedings of the National Academy of Sciences, 1995, 92(3): 836-840. [cited by applicant]

Lowe RF, et al., “Rational Design, Synthesis, and Structure—Activity Relationships of Aryltriazoles as Novel Corticotropin-Releasing Factor-1 Receptor Antagonists,” J. Med. Chem., 2005, 48(5):1540-1549. [cited by applicant]

Maciejewski-Lenoir D, et al., “Selective Impairment of Corticotropin-Releasing Factor1 (CRF1) Receptor-Mediated Function Using CRF Coupled to Saporin,” Endocrinology, 2000, 141(2):498-504. [cited by applicant]

Mackay, KB, et al., “Neuroprotective Effects of the CRF1 Antagonist R121920 after Permanent Focal Ischemia in the Rat,” Journal of Cerebral Blood Flow & Metabolism, 2001, 21(10): 1208-1214. [cited by applicant]

Malouf et al., “Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” Horm Res., 2006, 65(3):142-150. [cited by applicant]

Martínez V, et al., “Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice,” J Physiol., 2004, 556.1: 221-234. [cited by applicant]

Martinez-Aguayo et al., “Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia,” J Clin Endocrinol Metab., Dec. 2007, 92(12):4583-9. [cited by applicant]

McCarthy JR, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents,” Annual Reports in Medicinal Chemistry, 1999, 34: 11-20. [cited by applicant]

McCarthy JR, et al., “Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications,” Curr Pharm Des., 1999, 5(5):289-315. [cited by applicant]

Medlineplus.gov, “21-Hydroxylase Deficiency,” NIH US National Library of Medicine, Updated Aug. 18, 2020 [retrieved Dec. 13, 2021], retrieved from URL<https://medlineplus.gov/genetics/condition/21-hydroxylase-deficiency… [cited by applicant]

Mehta et al., “Adaptive increase in sample size when interim results are promising: a practical guide with examples,” Statistics in Medicine, 2011, 30(28):3267-3284. [cited by applicant]

Merke et al., “Congenital adrenal hyperplasia,” Lancet, 2005, 365:2125-2136. [cited by applicant]

Merke et al., “Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment,” Paediatr Drugs., 2001, 3(8):599-611. [cited by applicant]

Merke et al., “Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia,” J Clin Endoc… [cited by applicant]

Merke et al., “Management of adolescents with congenital adrenal hyperplasia,” Lancet Diabetes Endocrinol., Dec. 2013, 1(4):341-352. [cited by applicant]

Merke et al., “New ideas for medical treatment of congenital adrenal hyperplasia,” Endocrinol. Metab. Clin. North. Am., 2001, 30(1):121-135. [cited by applicant]

Merke et al., “NIH conference: Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” Ann. Intern. Med., 2002, 136:320-334. [cited by applicant]

Merke et al., “Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency,” N Engl J Med., Sep. 24, 2020, 383(13):1248-1261. [cited by applicant]

Meslamani et al., “Computational profiling of bioactive compounds using a target-dependent composite workflow,” J. Chem. Inf. Model., 2013, 2322-2333. [cited by applicant]

Migeon et al., “Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency,” Endocrinology and Metabolism Clinics of North America, 2001, 30(1):193-206. [cited by applicant]

Miller et al., “Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings,” Journal of Investigative Medicine, 2020, 68(1):16-25. [cited by applicant]

Million et al., “The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats, ” PLOS One, 2013, 8(9):e7… [cited by applicant]

Million M, et al., “A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats,” Brain Research, 2003, 985(1): 32-42. [cited by applicant]

Mims et al., “Plasma ACTH in Rats Following Medical Adrenalectomy,” Journal of the National Medical Association 69(3):145-147, 1977. [cited by applicant]

Morikawa S, et al., “Results from 28 years of Newborn Screening for Congenital Adrenal Hyperplasia in Sapporo,” Clin Pediatr Endocrinol., 2014, 23(2):35-43. [cited by applicant]

Mullins et al., “Brief psychiatric rating scale for children: quantitative scoring of medical records,” Psychiatry Research, 1986, 19(1):43-49. [cited by applicant]

Muthusamy et al., “Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis,” J Clin Endocrinol Metab., Sep. 2010, 95(9):4161-4172. [cited by applicant]

Nebesio TD, et al., “Growth and Reproductive Outcomes in Congenital Adrenal Hyperplasia,” Int J Pediatr Endocrinol., 2010, Article ID 298937, 1-10. [cited by applicant]

Nermoen et al., “Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway,” Eur J Endocrinol., Sep. 2010, 163(3):453-459. [cited by applicant]

[cited by applicant]

Newfield et al., “Crinecerfont (NBI-74788), a Novel CRF [cited by applicant]

Newfield et al., “Crinecerfont (NBI-74788), a novel CRF [cited by applicant]

Newfield R.S., “Acth receptor blockade: A novel approach to treat congenital adrenal hyperplasia, or Cushing's disease,” Medical Hypotheses, 2010, 74:705-706. [cited by applicant]

Nieves-Remacha et al., “Scale-up of N-alkylation reaction using phase-transfer catalysis with integrated separation in flow,” Reaction Chemistry & Engineering, 2019, 4(2):334-345. [cited by applicant]

Nokoff et al., “Sex differences in effects of obesity on reproductive hormones and glucose metabolism in early puberty,” The Journal of Clinical Endocrinology & Metabolism, 2019, 104(10):4390-4397. [cited by applicant]

Okuyama et al., “Receptor Binding, Behavioral, and Electrophysiological Profiles of Nonpeptide Corticotropin-Releasing Factor Subtype 1 Receptor Antagonists CRA1000 and CRA1001,” Journal of Pharmacology and Experimental… [cited by applicant]

Oray et al., “Long-term effect of glucocorticoids,” Expert Opinion on Drug Safety, 2016, 15(4):457-465. [cited by applicant]

Oster et al., “The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids,” Endocrine Reviews, 2017, 38(1):3-45. [cited by applicant]

Overall et al., “The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling,” Psychopharmacology Bulletin, 1988, 24(1):97-99. [cited by applicant]

Overall et al., “The brief psychiatric rating scale,” Psychological Reports, 1962, 10(3):799-812. [cited by applicant]

Overstreet et al., “Antidepressant-like effects of CRF [cited by applicant]

Owens et al., “Physiology and pharmacology of corticotropin-releasing factor,” Pharmacol Rev., Dec. 1991, 43(4):425-473. [cited by applicant]

Pang et al., “Worldwide Experience in Newborn Screening for Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency,” Pediatrics, 1988, 81(6):866-874. [cited by applicant]

Pang S, et al., “Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder,” Screening, 1993, 2:105-139. [cited by applicant]

Pelleymounter MA, et al., “Role of Corticotropin-Releasing Factor (CRF) Receptors in the Anorexic Syndrome Induced by CRF,” Journal of Pharmacology and Experimental Therapeutics, 2000, 293(3): 799-806. [cited by applicant]

Peplow et al., “Blood draws up to 3% of blood vol. in clinical trials are safe in children,” Acta Paediatrica, 2019, 108(5):940-944. [cited by applicant]

Perry SJ, et al., “Distinct Conformations of the Corticotropin Releasing Factor Type 1 Receptor Adopted following Agonist and Antagonist Binding Are Differentially Regulated,” J. Biol. Chem., 2005, 280(12): 11560-11568. [cited by applicant]

Philbert et al., “The CRF [cited by applicant]

Purnell et al., “Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women,” The Journal of Clini… [cited by applicant]

Ramos et al., “Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects,” Behavioral Brain Research, 2014, 265:69-75. [cited by applicant]

Ravens-Sieberer et al., “Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study,” Quality of Life Research, 2010, 19(6):887-897. [cited by applicant]

Reisch, “Substitution therapy in adult patients with congenital adrenal hyperplasia,” Best Practice & Research Clinical Endocrinology & Metabolism, 2015, 29(1):33-45. [cited by applicant]

Rief et al., “Mechanisms involved in placebo and nocebo responses and implications for drug trials,” Clinical Pharmacology & Therapeutics, 2011, 90(5):722-726. [cited by applicant]

Rivier CL, et al., “Role of Corticotropin-Releasing Factor Receptors Type 1 and 2 in Modulating the Rat Adrenocorticotropin Response to Stressors,” Endocrinology, 2003, 144(6): 2396-2403. [cited by applicant]

Rivier JE, et al., “Constrained Corticotropin Releasing Factor Antagonists (Astressin Analogues) with Long Duration of Action in the Rat,” J. Med. Chem. 1999, 42(16):3175-3182. [cited by applicant]

Rose & Hurst, “Plasma Cortisol and Growth Hormone Responses to Intravenous Catheterization,” J Hum Stress., Mar. 1975, 1(1):22-36. [cited by applicant]

Ross et al., “Improved biochemical control with dose reduction in chronic glucocorticoid therapy: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH),” Abstract su… [cited by applicant]

Ross et al., “Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control,” Abstract submitted to European Congress of Endocrinology 2… [cited by applicant]

Sarafoglou et al., “Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies,” Manuscript, The Journal of Clinical Endocrinology & Metabolism, 2021, 106(11):e4666-79. [cited by applicant]

Sarafoglou K, et al., “Impact of Hydrocortisone on Adult Height in Congenital Adrenal Hyperplasia—The Minnesota Cohort,” J Pediatr., 2014, 164(5):1141-1146. [cited by applicant]

Science.nichd.nih.gov [Online], “Pediatric Endocrinology Training Program,” 2020, [Retrieved on Mar. 6, 2023], retrieved from: URL<https://science.nichd.nih.gov/confluence/display/pe/Patient+Handouts+and+Support+Groups#… [cited by applicant]

Scott et al., “The use of the EQ-5D-Y health related quality of life outcome measure in children in the Western Cape, South Africa: psychometric properties, feasibility and usefulness—a longitudinal, analytical study,” … [cited by applicant]

Seymour et al., “The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review,” CNS Drug Reviews, 2003, 9(1):57-96. [cited by applicant]

Shargel et al., “Multiple-Dosage Regiments,” Applied Biopharmaceutics & Pharmacokinetics, 2012, 6th Edition, 31 pages. [cited by applicant]

Shargel et al., “Multiple-Dosage Regiments,” Applied Biopharmaceutics & Pharmacokinetics, 2016, 7th Edition, 33 pages. [cited by applicant]

Silva IN, et al., “Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia,” Archives of Disease in Childhood, 1997, 77:214-218. [cited by applicant]

Smith et al., “Measures of sleep: the insomnia severity index, medical outcomes study (MOS) sleep scale, Pittsburgh sleep diary (PSD), and Pittsburgh sleep quality index (PSQI),” Arthritis Care & Research: Official Jour… [cited by applicant]

Smith et al., “The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress,” Dialogues Clin Neurosci., 2006, 8:383-395. [cited by applicant]

Soliman et al., “Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin- releasing hormone analog,” Metabolism., May 1997, 46(5):513-517. [cited by applicant]

Somajni et al., “Neuropsychological assessment in prepubertal patients with congenital adrenal hyperplasia: preliminary study,” Minerva Pediatr., Feb. 2011, 63(1):1-9. [cited by applicant]

Speiser et al., “Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline,” J Clin Endocrinol Metab., Sep. 2010, 95(9):4133-60. [cited by applicant]

Speiser et al., “A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency,” International Journal of Pediatric Endocrinology 2010, 2010:4… [cited by applicant]

Speiser et al., “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,” J Clin Endocrinol Metab., 2018, 103(11):4043-4088. [cited by applicant]

Spierling et al., “Don't stress about CRF: assessing the translational failures of CRF [cited by applicant]

Steckler, “Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead?” Curr. Topics in Behav. Neurosciences, 2009, 415-428. [cited by applicant]

Stewart et al., “Development of a Biorelevant, Material-Sparing Membrane Flux Test for Rapid Screening of Bioavailability-Enhancing Drug Product Formulations,” Mol Pharm., 2017, 14(6):2032-2046. [cited by applicant]

Stewart et al., “Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency,” The Journal of Clinical Endocrinology & Metabolism, 2016, 101(12):4843-4850. [cited by applicant]

Stikkelbroeck et al., “High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia,” J Clin Endocrinol Metab., D… [cited by applicant]

Surget et al., “Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal,” Neuropsychopharmacology, 2009, 34:1363-1380. [cited by applicant]

Surget et al., “Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal,” Biol. Psychiatry, 2008, 64:293-301. [cited by applicant]

Teitelbaum, “Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress,” Am J Physiol Gastrointest Liver Physiol, 2008, 295: G452-G459. [cited by applicant]

Tellew et al., “Discovery ofNBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF [cited by applicant]

Thefreedictionary.com, “Baseline,” available on or before Nov. 7, 2016, via Internet Archive: Wayback Machine URL <https://web.archive.org/web/20161107132345/http:/medical-dictionary.thefreedictionary.com/baseline>, 3 p… [cited by applicant]

Therrell BL, et al., “Newborn Screening for Congenital Adrenal Hyperplasia,” Endocrinol Metab Clin North Am., 2001, 30(1):15-30. [cited by applicant]

Trakakis et al., “An update to 21-hydroxylase deficient congenital adrenal hyperplasia,” Gynecol Endocrinol., Jan. 2010, 26(1):63-71. [cited by applicant]

Trapp CM, et al. “Recommendations for Treatment of Nonclassic Congenital Adrenal Hyperplasia (NCCAH): an Update,” Steroids, 2012, 77(4):342-346. [cited by applicant]

Trapp et al., “Congenital adrenal hyperplasia: an update in children,” Curr Opin Endocrinol Diabetes Obes., 2011, 18(3):166-170. [cited by applicant]

Turcu et al., “Novel treatment strategies in congenital adrenal hyperplasia,” Curr Opin Endocrinol Diabetes Obes., 2016, 23(3):225-232. [cited by applicant]

Turcu et al., “Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency,” J Clin Endocrinol Metab., Mar. 2016, 101(3):1174-1180. [cited by applicant]

Turcu et al., “The Next 150 Years of Congenital Adrenal Hyperplasia,” J Steroid Biochem Mol Biol., Sep. 2015, 153:63-71. [cited by applicant]

Urani et al., “The Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, Prevent Stress-Induced Cognitive Impairment in Mice,” Pharmacology, Biochemistry… [cited by applicant]

U.S. Appl. No. 62/545,406, Howerton et al., “Corticotropin Releasing Factor Receptor Antagonists,” filed Aug. 14, 2017, 65 pages. [cited by applicant]

Vale et al., “Chemical and biological characterization of corticotropin releasing factor,” Recent Prog Horm Res., 1983, 39:245-270. [cited by applicant]

Vale et al., “Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin,” Science, 1981, 213:1394-1397. [cited by applicant]

Varni et al., “PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations,” Medical Care, 2001, 39(8):800-812. [cited by applicant]

Varni et al., “The PedsQL™ 4.0 as a school population health measure: feasibility, reliability, and validity,” Quality of Life Research, 2006, 15:203-215. [cited by applicant]

Varni et al., “The PedsQL™ family impact module: preliminary reliability and validity,” Health and Quality of Life Outcomes, 2004, 2:55. [cited by applicant]

Vickers et al., “Why Use Placebos in Clinical Trials? A Narrative Review of the Methodological Literature,” Journal of Clinical Epidemiology, 2000, 53(2):157-161. [cited by applicant]